X4 Pharmaceuticals, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $2.5M | $2.3M | $1.6M | $1.7M | $900.0K | $1.5M | $560.0K |
| Cost of Revenue | $1.6M | $598.0K | $364.0K | $351.0K | $326.0K | $4.7M | $302.0K | $227.0K |
| Gross Profit | $783.0K | $1.9M | $2.0M | $1.2M | $1.4M | $-3.8M | $1.2M | $333.0K |
| Gross Margin | 32.6% | 76.1% | 84.4% | 77.6% | 80.8% | -424.0% | 79.6% | 59.5% |
| Operating Expenses | ||||||||
| Research & Development | $15.1M | $15.5M | $18.5M | $17.3M | $18.4M | $18.5M | $21.7M | $19.2M |
| SG&A Expense | $8.5M | $7.0M | $7.4M | $11.6M | $9.5M | $15.0M | $15.1M | $15.7M |
| Operating Income | $-16.4M | $-20.3M | $-23.7M | $-27.5M | $-26.2M | $-9.4M | $-35.7M | $-34.5M |
| Operating Margin | -683.0% | -812.2% | -1,015.4% | -1,756.6% | -1,543.1% | -1,049.2% | -2,418.1% | -6,160.7% |
| Interest Expense | — | — | — | — | — | — | — | $2.4M |
| Pretax Income | $-16.2M | $-20.2M | $-23.9M | $-29.8M | $-25.7M | $316.0K | $-39.6M | $-36.7M |
| Income Tax Expense | $2.0K | $0 | $0 | $-30.0K | $37.0K | $34.0K | $258.0K | $15.0K |
| Net Income | $-16.2M | $-20.2M | $-23.9M | $-29.8M | $-25.7M | $282.0K | $-39.8M | $-36.7M |
| Net Margin | -673.2% | -809.6% | -1,025.1% | -1,903.9% | -1,514.2% | 31.3% | -2,696.1% | -6,552.9% |
| EPS (Basic) | $-0.13 | $-0.16 | $2.25 | $-0.12 | $-3.47 | $0.04 | $-5.93 | $-0.91 |
| EPS (Diluted) | $-0.13 | $-0.16 | $2.25 | $-0.12 | $-3.47 | $0.04 | $-5.91 | $-0.91 |
| Shares Outstanding (Basic) | 126.3M | 126.3M | 42.3M | 259.6M | 7.4M | 6.8M | 6.7M | 40.2M |
| Shares Outstanding (Diluted) | 126.3M | 126.3M | 42.3M | 259.6M | 7.4M | 6.9M | 6.7M | 40.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |